Why carry out this study?

To analyze the efficacy and safety of the coformulated fixed-dose combination bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) tablet compared to other approved antiretroviral regimens among people living with HIV by systematic meta-analysis of published clinical trial results.

What was learned from the study?

At week 48, the overall efficacy with BIC/FTC/TAF was not statistically significantly different from that with control regimens [odds ratio (OR) 1.01 (95% CI 0.79, 1.30)].

BIC/FTC/TAF had comparable safety profiles to control regimens: OR for all adverse effects (AEs) was 0.92 (95% CI 0.78, 1.09); OR for any grade 3 or grade 4 AEs was 0.96 (95% CI 0.66, 1.39); and OR for treatment-related AEs was 1.31 (95% CI 0.68, 2.53).